On October 14th, the Head of Research and Access at Sapphire Medical Clinics will be presenting the latest data on patients with Parkinson’s Disease from the UK Medical Cannabis Registry at the British Geriatrics Society Annual Conference. The conference, which is being held in Swansea, will cover the latest scientific research and the best clinical practice in care of older people.
The data which reports from the largest medical cannabis-specific registry in the UK, demonstrated a significant improvement in health-related quality of life at one month follow up.
This preliminary analysis, which reports from the largest medical cannabis-specific registry in the UK, showed a possible association with improved general health-related quality of life secondary to improvements in the ability to perform usual activities, as well as pain in those with Parkinson’s Disease.
Dr Simon Erridge, explained the findings further: “Parkinson’s Disease is one of the most common neurodegenerative conditions. Although there have been notable advances in management of the condition, there are some patients who still have symptoms despite most optimal medical therapy. For patients who meet this criterion who were enrolled in the UK Medical Cannabis Registry we have shown some very promising preliminary findings.
This is the first step in further evaluating medical cannabis in patients with Parkinson’s Disease, but it is important to highlight that further evaluation through randomised controlled trials will ultimately be necessary to identify if it may have a role for those with Parkinson’s Disease on a wider basis across the population.”
